Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The TQB2868 protein in this study targeted programmed cell death protein 1 (PD-1) and
transforming growth factor-β (TGF-β). The bifunctional fusion protein targets and neutralizes
TGF-β in the tumor microenvironment. On the basis of inhibiting PD-1 / programmed death
ligand 1 (PD-L1) pathway, T cells can restore activity, enhance immune response, and more
effectively improve the effect of inhibiting tumor occurrence and development.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.